Post date: Dec 22, 2011 11:51:16 AM
Which Compound to Select in Lead Optimization? Prospectively Validated Proteochemometric Models Guide Preclinical Development, PLoS ONE(2011) 6 (11), e27518 by Gerard J. P. van Westen, Jörg K. Wegner, Peggy Geluykens, Leen Kwanten, Inge Vereycken, Anik Peeters, Adriaan P. IJzerman, Herman W.T. van Vlijmen and Andreas Bender
and
A Novel Non-ribose Agonist, LUF5834, Engages Distinct Residues from that of Adenosine-like Ligands to Activate the Adenosine A2A Receptor, Molecular Pharmacology(2012) In Press Doi: 10.1124/mol.111.075937 by Robert Lane, Carmen Klein Herenbrink, Gerard J. P. van Westen, Jelle A Spoorendonk, Carsten Hoffmann, Adriaan P. IJzerman